HIV mutation literature information.


  Transcriptional inaccuracy threshold attenuates differences in RNA-dependent DNA synthesis fidelity between retroviral reverse transcriptases.
 PMID: 29330371       2018       Scientific reports
Result: Error rates of 3.3 x 10-5 were estimated for the O_K65R/V75I RT under those conditions (Table 4).
Result: In previous studies, we found that the mutant O_K65R/V75I RT was >15-fold more accurate than the HIV-1BH10 RT in forward mutation assays measuring fidelity of DNA-dependent DNA synthesis.
Result: Interestingly, the analysis of mutational spectra revealed that major hotspots obtained with O_K65R/V75I RT while reverse transcribing an RNA template synthesized at pH 7.9/6 mM Mg2.


  Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.
 PMID: 29084434       2018       AIDS research and human retroviruses
Introduction: However, in the 31 patients with no K65R present at S2, 6 had intermediate or high-level resistance to AZT: 4 were caused by TAM-2 DRMs, 1 by T215Y, and 1 by Q151M-complex mutations Q151M, A62V, V75I, F77L, F116Y.


  Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
 PMID: 30409215       2018       AIDS research and therapy
Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the RT, e.g., M41L, E44D, A62V, K65R, D67N, D67G, V75I, L100I, K103N, K103R, V188I, M184I, L210W, K219Q, Y318F, etc., although a number of minority mutations associated with resistance to PI (L10F, V11I, M46I/


  Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
 PMID: 29126456       2017       BMC research notes
Abstract: Overall, 32% (37/116) patients presented >= one major drug resistant mutation(s), with 29% (34/116) to nucleos(t)ide reverse transcriptase inhibitors (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] K219E/N/Q and 5% [2/43] A62V); 86% (37/43) to non-nulceos(t)ide reverse transcriptase inhibitors (30% [13/43] K103N/S/E, 26% [11/43] Y181C/V/F/L, 2% [1/43] L100I, 2% [1/43] F227L, 2% [1/43] P225H); and 2% (1/43


  Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya.
 PMID: 28178281       2017       PloS one
Table: V75I


  Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.
 PMID: 28333133       2017       Scientific reports
Result: Previous studies with prototypic HIV-1 RTs had shown that K65R produced large increases in the fidelity of DNA synthesis in the absence and in the presence of the NRTI-associated resistance mutation V75I.
Discussion: Furthermore, studies with the group O enzyme also showed the increased nucleotide selectivity of the double-mutant K65R/V75I in comparison with the RT bearing the single amino acid substitution V75I.


  Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.
 PMID: 28365230       2017       EBioMedicine
Result: Five NRTI-associated TRAMs occurred significantly more commonly in the thymidine analog group including V75I, T165L, M184V, D218E and L228H.
Result: Of the 83 TRAMs, 16 (21%; 16/83) were established NRTI-associated resistance mutations including A62V, K65R/N, T69deletion, K70E/Q/T/N, L74V/I, V75M/I/L, Y115F, and M184V/I and 40 (48%; 40/83) were established NNRTI-associated resistance mutations.


  Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
 PMID: 28396546       2017       Antimicrobial agents and chemotherapy
Abstract: Q151M and four associated mutations, A62V, V75I, F77L, and F116Y, were detected in patients failing therapies with dideoxynucleosides (didanosine [ddI], zalcitabine [ddC]) and/or zidovudine (AZT).


  Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
 PMID: 28533248       2017       Antimicrobial agents and chemotherapy
Abstract: A novel HIV-1 integrase mutation pattern, L74F V75I, which conferred resistance to first-generation integrase strand transfer inhibitors (INSTIs), was identified in a clinical case with virological failure under a raltegravir-based regimen.
Abstract: Addition of L74F V75I to N155H or G140S Q148H increased resistance levels to the second-generation INSTIs dolutegravir (>385- and 100-fold, respectively) and cabotegravir (153- and 197-fold, respectively).


  Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.
 PMID: 28553415       2017       The open microbiology journal
Abstract: Six-percent (n=6) had at least one HIVDR mutation, comprising NRTI-associated mutations, (M184V, T69D, T69N and V75I); NNRTI-associated mutations (G190A, K103N, V106M, Y181C) and thymidine analogue associated mutations (D67N, K70R, K219Q, L210W, M41L, T215Y).
Result: One participant had seven mutations, three were TAMs (L210W, T215Y and



   Filtrator